iSpecimen (NASDAQ:ISPC) Trading Down 9.5% – Here’s Why

iSpecimen Inc. (NASDAQ:ISPC) traded down 9.5% during trading on Tuesday . The stock traded as low as $1.32 and last traded at $1.33. Approximately 210,799 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,645,295 shares. The stock had previously closed at $1.47.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, iSpecimen presently has a consensus rating of “Sell”.

iSpecimen Stock Down 2.2%

The stock has a market cap of $3.38 million, a price-to-earnings ratio of -0.02 and a beta of 1.62. The stock’s fifty day moving average is $1.94 and its 200-day moving average is $3.96.

iSpecimen (NASDAQ:ISPC) last posted its earnings results on Friday, August 14th. The company reported ($0.98) earnings per share for the quarter. iSpecimen had a negative return on equity of 524.39% and a negative net margin of 2,445.40%.The firm had revenue of $0.15 million during the quarter.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.